Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Autologous cancer vaccine - Vaccinogen

Drug Profile

Autologous cancer vaccine - Vaccinogen

Alternative Names: Active specific immunotherapy - Vaccinogen; ASI - Vaccinogen; Autologous tumour cell vaccine - Vaccinogen; Colon cancer vaccine - Intracel; OncoVAX

Latest Information Update: 07 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Intracel Corporation
  • Developer Intracel Corporation; National Cancer Institute (USA); Vaccinogen
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Colorectal cancer
  • No development reported Malignant melanoma; Renal cancer
  • Discontinued Ovarian cancer

Most Recent Events

  • 07 Jan 2020 Autologous cancer vaccine is still in phase III trial for Colorectal cancer (Adjuvant therapy, Early-stage disease, Prevention of relapse) in USA (NCT02448173)
  • 07 Jan 2020 No development reported - Phase-II for Colorectal cancer (Combination therapy, Adjuvant therapy) in USA (Intradermal)
  • 18 Aug 2017 Vaccinogen's autologous cancer vaccine is at phase II development stage for Colorectal cancer (Combination therapy, Adjuvant therapy) in Netherlands and USA (Intradermal) (Vaccinogen website, August 2017)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top